Prof. Ian Pavord of the Department of Respiratory Medicine, Allergy and Thoracic Surgery, Glenfield Hospital, Leicester, UK, who conducted the post-hoc analysis stated: "With this analysis, we identify a level of peripheral blood eosinophil cell counts that identifies the patients who are more dependent on ICS to maintain asthma control. These patients had a better response to CYT003, further supporting the potential clinical benefit of CYT003 in allergic asthma patients."
 Beeh et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013 Mar;131(3):866-874).
 Pavord et al. Effect of baseline eosinophil count on response to CYT003-QbG10 in patients with persistent allergic asthma. [ERS abstract P3156; Date: September 9, 2013; Time: 14:45-16:35; Room 3.7; Session 311]
Cytos Biotechnology AG will host a conference call to discuss the content of this press release on 17 September 2013, at 9 a.m. EDT / 1500 CET.
The dial-in numbers are:
+41 (0) 58 310 50 00 (Europe)
+44 (0) 203 059 58 62 (UK)
+ 1 (1) 631 570 5613 (USA)
The presentation can be viewed clinking at the following link:
About the P2a clinical study
The published study is a randomized, double-blind, placebo-controlled trial in patients with persistent allergic asthma requiring long-term treatment with inhaled corticosteroids (ICS). The study took place at five centers in Germany and recruited 63 patients who received 7 weekly to bi-weekly subcutaneous injections, with efficacy assessment during 12 weeks. ICS treatment was withdrawn in tw
|SOURCE Cytos Biotechnology Ltd|
Copyright©2012 PR Newswire.
All rights reserved